Home 2018-04-16T17:56:39+00:00

ProLung: Predictive Analytics for
Rapid Risk Stratification of Lung Cancer*

ProLung is the world leader in accurate, non-invasive, and radiation-free predictive analytics for the rapid risk stratification of lung cancer.

– – It’s About Time – –

Lung cancer has the lowest 5-year survival rate of all major cancers.

Successful treatment of lung cancer is dependent on early detection.

Time to diagnosis directly affects outcome and survival rates.

The need for a predictive analytics solution is clear.

 .

Take the Lung Cancer Screening Quiz at SavedByTheScan.org, courtesy of the American Lung Association

TAKE THE QUIZ

The ProLung Test

The only predictive analytics technology available for the lung*

The ProLung Test is an innovative predictive analytics technology and non-invasive test for the risk stratification of indeterminate pulmonary nodules that can lead to lung cancer. It uses precision proprietary volume-averaging bioconductance technology to measure the difference in conductivity between malignant and benign lung tissue. The patient’s test results are analyzed to produce a personalized and predictive score indicating the likelihood that a particular lesion in the lungs is malignant.

ACCURATE

The ProLung Test has demonstrated accuracy in published clinical trials.
.

More

NON-INVASIVE

The ProLung Test is non-invasive and emits no radiation to the patient.
.

More

RAPID

The ProLung Test requires less than 30 minutes to perform and produces results within 24 hours.

More

Group of people icon.

INVESTORS

ProLung’s mission is to make a difference in time by striving to improve outcomes for potential lung cancer patients through predictive analytics technologies; facilitate cost savings to patients, payers, and providers; and provide a fair return on investment to shareholders and other stakeholders.

We are committed to making a positive and significant impact on the healthcare community and to being socially responsible in all our endeavors.

CONFERENCE APPEARANCES, COMPANY NEWS,
FINANCIAL REPORTS, AND MORE…

INVESTOR RELATIONS
Vision Icon

COMPANY UPDATES

ON THE ROAD TO IPO: PROLUNG, INC. S1 STATEMENT FILED WITH  SEC

PRESS RELEASES
INVESTOR CALENDAR